Skip to main content
SpringerLink
Log in

Recent Developments in the Treatment of Diabetes Type 2

  • Chapter
Prevention and Treatment of Age-related Diseases

  • 1052 Accesses

Abstract

Diabetes type 2 (T2DM) is a life-long metabolic disease that develops commonly in adulthood as a consequence of an unhealthy life style and genetic predisposition. T2DM is the most common form of diabetes, resulting from both insulin resistances in target organs and insufficient insulin production from pancreas beta cells. T2DM is characterized by increased plasma glucose and insulin levels as well as dyslipidemia. If left untreated chronic diseases will develop that result in a higher mortality risk. ∈dent The prevalence of type 2 diabetes worldwide has increased dramatically in recent times in part due to changes in diet and physical activity levels. Also, several genes underlying monogenic forms of diabetes as well as polymorphic variants have been identified that can contribute to the etiology of the disease. ∈dent A number of treatment strategies exist for T2DM that tackle several of the symptoms. Anti-obesity drugs and PPAR agonists are likely to become efficient pharmacological remedies to prevent further health problems in individuals with T2DM

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abdelrahman, M., Sivarajah, A. and Thiemermann, C. (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res., 65(4): 772–781.

    Article  PubMed  CAS  Google Scholar 

  • Anderson, D.C., Jr. (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann. Pharmacother., 39(1): 102–109.

    PubMed  CAS  Google Scholar 

  • Anderson, J.W. (2006) Diabetes mellitus: medical nutrition therapy. In: Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. eds. (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams & Wilkins. 2069 pp.

    Google Scholar 

  • Asakawa, A., Inui, A., Kaga, T., Katsuura, G., Fujimiya, M., Fujino, M.A. and Kasuga, M. (2003) Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 52(7): 947–952.

    Article  PubMed  CAS  Google Scholar 

  • Asfaha, S. and Padwal, R. (2005) Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. Curr. Hypertens. Rep., 7(5): 314–322.

    PubMed  CAS  Google Scholar 

  • Atkins, R.C. (2001) Age-defying diet. St. Martin’s paperbacks.

    Google Scholar 

  • Auwerx, J. (2006) Improving metabolism by increasing energy expenditure. Nat. Med., 12: 44–45.

    Article  PubMed  CAS  Google Scholar 

  • Barroso, I. (2005) Complex disease: pleiotropic gene effects in obesity and type 2 diabetes. Eur J Hum Genet., 13(12): 1243–1244.

    Article  PubMed  CAS  Google Scholar 

  • Bays, H.E. (2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res., 12(8): 1197–1211.

    Article  PubMed  CAS  Google Scholar 

  • Bedu, E., Wahli, W. and Desvergne, B. (2005) Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin. Ther. Targets, 9(4): 861–873.

    Article  PubMed  CAS  Google Scholar 

  • Berger, J.P., Akiyama, T.E. and Meinke, P.T. (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci., 26(5): 244–251.

    Article  PubMed  CAS  Google Scholar 

  • CDC, Centers for disease control and prevention, USA, 2006. http://www.cdc.gov/nccdphp/dnpa/obesity/ defining.htm

    Google Scholar 

  • Corton, J.C. and Brown-Borg, H.M. (2005) Peroxisome Proliferator-Activated Receptor {gamma} Coactivator 1 in Caloric Restriction and Other Models of Longevity. J Gerontol A Biol Sci Med Sci., 60(12): 1494–1509.

    PubMed  Google Scholar 

  • Cox, S.L. (2005) Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc)., 41(9): 579–587.

    Article  CAS  Google Scholar 

  • Cunard, R. (2005) The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Investig. Drugs, 6: 467–472.

    PubMed  CAS  Google Scholar 

  • de Luca, C. and Olefsky, J.M. (2006) Stressed out about obesity and insulin resistance. Nat. Med., 12(1): 41–42.

    Article  PubMed  CAS  Google Scholar 

  • Despres, J.P., Golay, A., Sjostrom, L., Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 353(20): 2121–2134.

    Google Scholar 

  • Diabetes Prevention Program Research Group (2005) Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care, 28(1): 138–144.

    Google Scholar 

  • Durant, N. and Cox, J. (2005) Current treatment approaches to overweight in adolescents. Curr. Opin. Pediatr., 17(4): 454–459.

    Article  PubMed  Google Scholar 

  • Dwyer, J.T., Allison, D.B. and Coates, P.M. (2005) Dietary supplements in weight reduction. J. Am. Diet Assoc., 105(5 Suppl 1): S80–86.

    Article  PubMed  CAS  Google Scholar 

  • English, P. and Williams, G. (2001) Type 2 diabetes. Martin Dunitz Ltd. 103 pp.

    Google Scholar 

  • Erion, M.D., van Poelje, P.D., Dang, Q., Kasibhatla, S.R., Potter, S.C., Reddy, M.R., Reddy, K.R., Jiang, T. and Lipscomb, W.N. (2005) MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc. Natl. Acad. Sci. USA, 102(22): 7970–7975.

    Article  PubMed  CAS  Google Scholar 

  • Etgen, G.N. and Mantlo, N. (2003) PPAR ligands for metabolic disorders. Curr. Top. Med. Chem., 3: 1649–1661.

    Article  PubMed  CAS  Google Scholar 

  • Evans, R.M., Barish, G.D. and Wang, Y.X. (2004) PPARs and the complex journey to obesity. Nat. Med., 10: 355–361.

    Article  PubMed  CAS  Google Scholar 

  • Fajas, L., Debril, M.-B. and Auwerx, J. (2001) PPARγ: An essential role in metabolic control. Nutr. Metab. Cardiovasc. Dis., 11: 64–69.

    PubMed  CAS  Google Scholar 

  • FDA, Federal drug administration, 2006. http://www.fda.gov

    Google Scholar 

  • Feinstein, D.L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V. and Russo, C.D. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol., 70(2): 177–188.

    Article  PubMed  CAS  Google Scholar 

  • Ferre, P. (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes, 53 Suppl 1: S43–S50.

    Article  PubMed  CAS  Google Scholar 

  • Filippatos, T.D., Kiortsis, D.N., Liberopoulos, E.N., Mikhailidis, D.P. and Elisaf, M.S. (2005a) A review of the metabolic effects of sibutramine. Curr. Med. Res. Opin., 21(3): 457–468.

    Article  CAS  Google Scholar 

  • Filippatos, T.D., Kiortsis, D.N., Liberopoulos, E.N., Georgoula, M., Mikhailidis, D.P., Elisaf, M.S. (2005b) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr. Med. Res. Opin., 21(12): 1997–2006.

    Article  CAS  Google Scholar 

  • Fredenrich, A. and Grimaldi, P.A. (2005) PPARdelta: an uncompletely known PPAR nuclear receptor. Diabetes Metab., 31: 23–27.

    Article  PubMed  CAS  Google Scholar 

  • Friedman, M. and McLellan, A. (2006) Healing diabetes: complementary naturopathic and drug treatments. Ccnm press. 272 pp.

    Google Scholar 

  • Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G. and Piomelli, D. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature, 425: 90–93.

    Article  PubMed  CAS  Google Scholar 

  • Gallwitz, B. (2005) Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol., 4(6): 361–370.

    Article  PubMed  CAS  Google Scholar 

  • Gauthier, B.R. and Wollheim, C.B. (2006) MicroRNAs: ‘ribo-regulators’ of glucose homeostasis. Nat. Med., 12: 36–38.

    Article  PubMed  CAS  Google Scholar 

  • Gloyn, A.L. (2003) Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mutat., 22(5): 353–362.

    Article  PubMed  CAS  Google Scholar 

  • Hakim, N., Stratta, R. and Gray, D. (eds.) (2002) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.

    Google Scholar 

  • Hammarstedt, A., Andersson, C.X., Rotter Sopasakis, V. and Smith, U. (2005) The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids., 73(1): 65–75.

    Article  CAS  Google Scholar 

  • Hansen, L. and Pedersen, O. (2005) Genetics of type 2 diabetes mellitus: status and perspectives. Diabetes Obes. Metab., 7(2): 122–135.

    Article  PubMed  CAS  Google Scholar 

  • Harrity, T., Farrelly, D., Tieman, A., Chu, C., Kunselman, L., Gu, L., Ponticiello, R., Cap, M., Qu, F., Shao, C., Wang, W., Zhang, H., Fenderson, W., Chen, S., Devástale, P., Jeon, Y., Seethala, R., Yang, W.P., Ren, J., Zhou, M., Ryono, D., Biller, S., Mookhtiar, K.A., Wetterau, J., Gregg, R., Cheng, P.T. and Hariharan, N. (2006) Muraglitazar, a novel dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor activator, improves diabetes and other metabolic abnormalities and preserves {beta}-Cell Function in db/db mice. Diabetes, 55(1): 240–248.

    Article  PubMed  CAS  Google Scholar 

  • Hauner, H. (2004) Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol., 3(4): 223–232.

    Article  PubMed  CAS  Google Scholar 

  • Hill, J.O., Catenacci, V.A. and Wyatt, H.R. (2006). Obesity: etiology. Chapter 63. pp 1013–1028. In Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. (eds.) (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams and Wilkins.2069 pp.

    Google Scholar 

  • Hoivik, D.J., Qualls, C.W. Jr, Mirabile, R.C., Cariello, N.F., Kimbrough, C.L., Colton, H.M., Anderson, S.P., Santostefano, M.J., Morgan, R.J., Dahl, R.R., Brown, A.R., Zhao, Z., Mudd, P.N. Jr, Oliver, W.B. Jr, Brown, H.R. and Miller, R.T. (2004) Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 25(9): 1757–1769.

    Article  PubMed  CAS  Google Scholar 

  • Hovens, M.M., Tamsma, J.T., Beishuizen, E.D. and Huisman, M.V. (2005) Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. Drugs, 65(4): 433–445.

    Article  PubMed  CAS  Google Scholar 

  • Jiang, G. and Zhang, B.B. (2005) Modulation of insulin signalling by insulin sensitizers. Biochem. Soc. Trans., 33(Pt 2): 358–361.

    Google Scholar 

  • Kadowaki, T. and Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocr. Rev., 26(3): 439–451.

    Article  PubMed  CAS  Google Scholar 

  • Kahn, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C. and Smith, R.J. (eds.) (2005) Joslin’s diabetes mellitus, 14th ed. Lippincott Williams and Wilkins. 1209 pp.

    Google Scholar 

  • Kaplan, L.H. (2005) Pharmacological therapies for obesity. Gastroenterol. Clin. North Am., 34(1): 91–104.

    Google Scholar 

  • Karanam, M., Song, Z. and Jindal, R.M. (2002) Gene therapy for diabetes. Chapter 21. 291–304. In Hakim, N., Stratta, R. and Gray, D. (eds.) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.

    Google Scholar 

  • Kim, S.H., Hyun, S.H. and Choung, S.Y. (2006) Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J. Ethnopharmacol. In press.

    Google Scholar 

  • Kiortsis, D.N., Filippatos, T.D. and Elisaf, M.S. (2005) The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab., 31(1): 15–22.

    Article  PubMed  CAS  Google Scholar 

  • Kojima, I. and Umezawa, K. (2006) Conophylline: A novel differentiation inducer for pancreatic beta cells. Int. J. Biochem. Cell. Biol., In press.

    Google Scholar 

  • Kota, B.P., Huang, T.H. and Roufogalis, B.D. (2005) An overview on biological mechanisms of PPARs. Pharmacol. Res., 51(2): 85–94.

    Article  PubMed  CAS  Google Scholar 

  • Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Kadowaki, T. et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4(4): 597–609.

    Article  PubMed  CAS  Google Scholar 

  • Kulkarni, R.N. (2004) The islet β-cell. Int. J. Biochem. Cell Biol. 36: 365–371.

    Article  PubMed  CAS  Google Scholar 

  • Kurtz, T.W. and Pravenec, M. (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens., 22(12): 2253–2261.

    Article  PubMed  CAS  Google Scholar 

  • Kusminski, C.M., McTernan, P.G. and Kumar, S. (2005) Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond)., 109(3): 243–256.

    Article  CAS  Google Scholar 

  • Laakso, M. (2005) Prevention of type 2 diabetes. Curr Mol Med., 5(3): 365–374.

    Article  PubMed  CAS  Google Scholar 

  • Lazar, M.A. (2005) PPAR gamma, 10 years later. Biochimie, 87(1): 9–13.

    Article  PubMed  CAS  Google Scholar 

  • Lebovitz, H.E. (2005) Management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes. Chapter 41.687–710. In: Kahn, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C. and Smith, R.J. (eds.) (2005) Joslin’s diabetes mellitus, 14th ed. Lippincott Williams & Wilkins. 1209 pp.

    Google Scholar 

  • List, J.F. and Habener, J.F. (2004) Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab., 286(6), E875–E881.

    Google Scholar 

  • Lo Verme, J., Gaetani, S., Fu, J., Oveisi, F., Burton, K. and Piomelli, D. (2005) Regulation of food intake by oleoylethanolamide. Cell. Mol. Life Sci., 62(6): 708–716.

    Article  PubMed  CAS  Google Scholar 

  • Lowell, B.B. and Shulman, G.I. (2005) Mitochondrial dysfunction and type 2 diabetes. Science, 307(5708): 384–387.

    Article  PubMed  CAS  Google Scholar 

  • Luquet, S., Lopez-Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M. and Grimaldi, P.A. (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J., 17(15): 2299–2301.

    PubMed  CAS  Google Scholar 

  • Luquet, S., Gaudel, C., Holst, D., Lopez-Soriano, J., Jehl-Pietri, C., Fredenrich, A. and Grimaldi, P.A. (2005) Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta, 1740(2): 313–317.

    PubMed  CAS  Google Scholar 

  • Malecki, M.T. (2005) Genetics of type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 68 Suppl1: S10–S21.

    CAS  Google Scholar 

  • Mathys, M. (2005) Pharmacologic agents for the treatment of obesity. Clin. Geriatr. Med., 21(4): 735–746.

    Article  PubMed  Google Scholar 

  • Mogensen, J.P., Jeppesen, L., Bury, P.S., Pettersson, I., Fleckner, J., Nehlin, J., Frederiksen, K.S., Albrektsen, T., Din, N., Mortensen, S.B., Svensson, L.A., Wassermann, K., Wulff, E.M., Ynddal, L. and Sauerberg, P. (2003) Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorg. Med. Chem. Lett., 13: 257–260.

    Article  PubMed  CAS  Google Scholar 

  • Nakamichi, Y., Kikuta, T., Ito, E., Ohara-Imaizumi, M., Nishiwaki, C., Ishida, H. and Nagamatsu, S. (2003) PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells. Biochem. Biophys. Res. Commun., 306(4): 832–836.

    Article  PubMed  CAS  Google Scholar 

  • Nehlin, J.O., Mogensen, J.P., Petterson, I., Jeppesen, L., Fleckner, J., Wulff, E.M. and Sauerberg, P. (2006) Selective PPAR agonists for the treatment of diabetes type 2. Annals N.Y. Acad. Sci. In press.

    Google Scholar 

  • Oliver, W.R. Jr, Shenk, J.L., Snaith, M.R., Russell, C.S., Plunket, K.D., Bodkin, N.L., Lewis, M.C., Winegar, D.A., Sznaidman, M.L., Lambert, M.H., Xu, H.E., Sternbach, D.D., Kliewer, S.A., Hansen, B.C. and Willson, T.M. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci.USA, 98: 5306–5311.

    Article  PubMed  CAS  Google Scholar 

  • Owen, M.R., Doran, E. and Halestrap, A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J., 348 Pt. 3: 607–614.

    Google Scholar 

  • Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.H., Iwakoshi, N.N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L.H. and Hotamisligil, G.S. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 306(5695): 457–461.

    Article  PubMed  CAS  Google Scholar 

  • Padwal, R., Majumdar, S.R., Johnson, J.A., Varney, J. and McAlister, F.A. (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 28(3): 736–744.

    Article  PubMed  CAS  Google Scholar 

  • Park, S.Y., Cho, Y.R., Finck, B.N., Kim, H.J., Higashimori, T., Hong, E.G., Lee, M.K., Danton, C., Deshmukh, S., Cline, G.W., Wu, J.J., Bennett, A.M., Rothermel, B., Kalinowski, A., Russell, K.S., Kim, Y.B., Kelly, D.P. and Kim, J.K. (2005) Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes, 54(9): 2514–2524.

    Article  PubMed  CAS  Google Scholar 

  • Poulsen, M.K., Henriksen, J.E., Hother-Nielsen, O. and Beck-Nielsen, H. (2003) The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care, 26(12): 3273–3279.

    Article  PubMed  CAS  Google Scholar 

  • Press, M. (2002) The nature of the problem: why do we need pancreatic transplantation? Chapter 2. In: Hakim, N., Stratta, R. and Gray, D. (eds.) (2002) Pancreas and islet transplantation. Oxford Univ. Press. 378 pp.

    Google Scholar 

  • Puigserver, P. and Rodgers, J.T. (2006) Foxa2, a novel transcriptional regulator of insulin sensitivity. Nat Med., 12(1): 38–39.

    Article  PubMed  CAS  Google Scholar 

  • Puigserver, P. (2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int.J.Obes.(Lond), 29 Suppl 1: S5–S9.

    Article  CAS  Google Scholar 

  • Rangwala, S.M. and Lazar, M.A. (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci., 25: 331–336.

    Article  PubMed  CAS  Google Scholar 

  • Reaven, G.M. (2005) The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr., 25: 391–406.

    Article  PubMed  CAS  Google Scholar 

  • Rhodes, C.J. (2005) Type 2 diabetes-a matter of beta-cell life and death? Science, 307(5708): 380–384.

    Article  PubMed  CAS  Google Scholar 

  • Ricketts, M.L., Moore, D.D., Banz, W.J., Mezei, O. and Shay, N.F. (2005) Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J. Nutr. Biochem., 16(6): 321–330.

    Article  CAS  Google Scholar 

  • Rimando, A.M., Nagmani, R., Feller, D.R. and Yokohama, W. (2005) Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem., 53(9): 3403–3407.

    Article  PubMed  CAS  Google Scholar 

  • Rosen, E.D. and Spiegelman, B.M. (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell Growth. J. Biol. Chem., 276: 37731–37734.

    Article  PubMed  CAS  Google Scholar 

  • Rotella, C.M., Pala, L. and Mannucci, E. (2005) Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J. Endocrinol. Invest., 28(8): 746–758.

    PubMed  CAS  Google Scholar 

  • Sacerdote, A., Weiss, K., Tran, T., Rokeya Noor, B. and McFarlane, S.I. (2005) Hypertension in patients with Cushing’s disease: pathophysiology, diagnosis, and management. Curr. Hypertens. Rep., 7(3): 212–218.

    PubMed  Google Scholar 

  • Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo, M., Roque, M. and Moher, D. (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 3: CD002966.

    Google Scholar 

  • Sauerberg, P., Pettersson, I., Jeppesen, L., Bury, P.S., Mogensen, J.P., Wassermann, K., Brand, C.L., Sturis, J., Woldike, H.F., Fleckner, J., Andersen, A.S., Mortensen, S.B., Svensson, L.A., Rasmussen, H.B., Lehmann, S.V., Polivka, Z., Sindelar, K., Panajotova, V., Ynddal, L. and Wulff, E.M. (2002) Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem., 45: 789–804.

    Article  PubMed  CAS  Google Scholar 

  • Sauerberg, P., Bury, P.S., Mogensen, J.P., Deussen, H.J., Pettersson, I., Fleckner, J., Nehlin, J., Frederiksen, K.S., Albrektsen, T., Din, N., Svensson, L.A., Ynddal, L., Wulff, E.M., and Jeppesen, L. (2003) Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem., 46: 4883–4894.

    PubMed  CAS  Google Scholar 

  • Sauerberg, P., Mogensen, J.P., Jeppesen, L., Svensson, L.A., Fleckner, J., Nehlin, J., Wulff, E.M. and Pettersson, I. (2005) Structure-activity relationships of dimeric PPAR agonists. Bioorg. Med. Chem. Lett., 15: 1497–1500.

    Article  PubMed  CAS  Google Scholar 

  • Scher, J.U. and Pillinger, M.H. (2005) 15d-PGJ2: the anti-inflammatory prostaglandin? Clin. Immunol., 114(2): 100–109.

    Article  PubMed  CAS  Google Scholar 

  • Schulze, M.B. and Hu, F.B. (2005) Primary prevention of diabetes: what can be done and how much can be prevented? Annu. Rev. Public Health, 26: 445–467.

    Article  Google Scholar 

  • Scott, R., Best, J., Forder, P., Taskinen, M.R., Simes, J., Barter, P., Keech, A. and FIELD Study Investigators (2005) Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol., 4: 13.

    Google Scholar 

  • Seeley, R.J. and Tschop, M. (2006) How diabetes went to our heads. Nat Med., 12(1): 47–49.

    Article  PubMed  CAS  Google Scholar 

  • Shils, M.E., Shike, M., Ross, C.A., Caballero, B. and Cousins, R.J. eds. (2006) Modern nutrition in health and disease. 10th ed. Lippincott, Williams and Wilkins. 2069 pp.

    Google Scholar 

  • Soria, B., Roche, E., Reig, J.A. and Martin, F. (2005) Generation of insulin-producing cells from stem cells. Novartis Found Symp. 265: 158–167; discussion 167–73, 204–11.

    Google Scholar 

  • Sorkin, J.D., Muller, D.C., Fleg, J.L. and Andres, R. (2005) The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care, 28(11): 2626–2632.

    Article  PubMed  Google Scholar 

  • Speight, T.M. and Holford, N.H.G. (eds.) (1997) Avery’s drug treatment. 4th ed. Adis International Ltd.

    Google Scholar 

  • Spiegelman, B.M. and Flier, J.S. (2001) Obesity and the regulation of energy balance. Cell, 104: 531–543.

    Article  PubMed  CAS  Google Scholar 

  • Staels, B. and Fruchart, J.C. (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 54(8): 2460–2470.

    Article  PubMed  CAS  Google Scholar 

  • Staels, B. (2005) PPARgamma and atherosclerosis. Curr. Med. Res. Opin., 21 Suppl 1: S13–S20 (2005).

    Google Scholar 

  • Steinbeck, K. (2005) Childhood obesity. Treatment options. Best Pract. Res. Clin. Endocrinol. Metab., 19(3): 455–469.

    Article  Google Scholar 

  • Stumvoll, M., Goldstein, B.J.. and van Haeften, T.W. (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365: 1333–1346.

    Google Scholar 

  • Sturis, J., Gotfredsen, C.F., Romer, J., Rolin, B., Ribel, U., Brand, C.L., Wilken, M., Wassermann, K., Deacon, C.F., Carr, R.D. and Knudsen, L.B. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br. J. Pharmacol., 140(1): 123–132.

    Article  PubMed  CAS  Google Scholar 

  • Tan, N.S., Michalik, L., Desvergne, B. and Wahli, W. (2005) Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol., 93(2–5): 99–105.

    Google Scholar 

  • Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R.X., Tachibana, K., Watanabe, Y., Uchiyama, Y., Sumi, K., Iguchi, H., Ito, S., Doi, T., Hamakubo, T., Naito, M., Auwerx, J., Yanagisawa, M., Kodama, T. and Sakai, J. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA, 100(26): 15924–15929.

    Article  PubMed  CAS  Google Scholar 

  • Taylor, S.I. (1999) Deconstructing type 2 diabetes. Cell, 97: 9–12.

    Article  PubMed  CAS  Google Scholar 

  • Toyoshima, Y., Gavrilova, O., Yakar, S., Jou, W., Pack, S., Asghar, Z., Wheeler, M.B. and LeRoith, D. (2005) Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology, 146(9): 4024–4035.

    Article  PubMed  CAS  Google Scholar 

  • Unger, R.H. (2006) Klotho-induced insulin resistance: a blessing in disguise? Nat. Med., 12(1): 56–57.

    Article  PubMed  CAS  Google Scholar 

  • van Raalte, D.H., Li, M., Pritchard, P.H. and Wasan, K.M. (2004) Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res., 21: 1531–1538.

    Article  PubMed  Google Scholar 

  • Verma, N.K., Singh, J. and Dey, C.S. (2004) PPAR-gamma expression modulates insulin sensitivity in C2C12 skeletal muscle cells. Br. J. Pharmacol., 143(8): 1006–1013.

    Article  PubMed  CAS  Google Scholar 

  • Wadman, M. (2006) Rimonabant adds appetizing choice to slim obesity market. Nat. Med., 12, 27 (2006).

    Google Scholar 

  • Wang, Y.L., Frauwirth, K.A., Rangwala, S.M., Lazar, M.A. and Thompson, C.B. (2002) Thiazolidinedione Activation of Peroxisome Proliferator-activated Receptor γ Can Enhance Mitochondrial Potential and Promote Cell Survival. J. Biol. Chem., 277: 31781–317888.

    Article  PubMed  CAS  Google Scholar 

  • Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H. and Evans, R.M. (2003) Peroxisome-Proliferator-activated receptor d activates fat metabolism to prevent obesity. Cell, 113: 159–170.

    Article  PubMed  CAS  Google Scholar 

  • WHO, World Health Organisation. 2006. http://www.who.int/diabetes/facts/en/

    Google Scholar 

  • Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047–1053.

    Article  PubMed  Google Scholar 

  • Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047–1053.

    Article  PubMed  Google Scholar 

  • Yach, D., Stuckler, D., and Brownell, K.D. (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat. Med., 12(1): 62–66.

    Article  PubMed  CAS  Google Scholar 

  • Youssef, J.A. and Badr, M.Z. (2005) Aging and enhanced hepatocarcinogenicity by peroxisome proliferator-activated receptor alpha agonists. Ageing Res. Rev., 4: 103–118.

    Article  PubMed  CAS  Google Scholar 

  • Yu, S., Matsusue, K., Kashireddy, P., Cao, W.Q., Yeldandi, V., Yeldandi, A.V., Rao, M.S., Gonzalez, F.J. and Reddym, J.K. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem., 278(1): 498–505.

    Article  PubMed  CAS  Google Scholar 

  • Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D., Liang, J., Li, E., Song, Q. and Chen, Y.E. (2004a) Selective disruption of PPARg2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. USA, 101: 10703–10708.

    Article  CAS  Google Scholar 

  • Zhang, F., Lavan, B. and Gregoire, F.M. (2004b) Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News Perspect., 17(10): 661–669.

    Article  Google Scholar 

  • Zingarelli, B. and Cook, J.A. (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock, 23(5): 393–399.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology, Odense University Hospital & University of Southern Denmark, 5000 Odense, Denmark

    Jan O. Nehlin

Authors
  1. Jan O. Nehlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Danish Centre for Molecular Gerontology, University of Aarhus, Denmark

    Suresh I.S. Rattan

  2. University Hospital of Odense, Denmark

    Moustapha Kassem

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer

About this chapter

Cite this chapter

Nehlin, J.O. (2006). Recent Developments in the Treatment of Diabetes Type 2. In: Rattan, S.I., Kassem, M. (eds) Prevention and Treatment of Age-related Diseases. Springer, Dordrecht. https://doi.org/10.1007/1-4020-5058-5_8

Download citation

Publish with us

Policies and ethics

Search

Navigation